[8-K] Tonix Pharmaceuticals Holding Corp. Reports Material Event
Tonix Pharmaceuticals Holding Corp. reported that it announced operating results for the quarter ended June 30, 2025. The company states a press release discussing those results is filed as Exhibit 99.01 and is incorporated by reference into this report. The filing confirms Tonix's common stock trades under the symbol TNXP on The NASDAQ Capital Market.
The filing is a notice of the release of operating results rather than detailed financial statements within the form itself; the cover page interactive XBRL file is referenced as Exhibit 104, and the report is signed by the company鈥檚 Chief Financial Officer, Bradley Saenger.
Tonix Pharmaceuticals Holding Corp. ha reso noto di aver comunicato i risultati operativi relativi al trimestre chiuso il 30 giugno 2025. La societ脿 indica che il comunicato stampa che illustra tali risultati 猫 depositato come Exhibit 99.01 e viene incorporato per riferimento nel presente rapporto. Il documento conferma che le azioni ordinarie di Tonix sono negoziate con il simbolo TNXP sul NASDAQ Capital Market.
Si precisa che la presente comunicazione riguarda la pubblicazione dei risultati operativi e non contiene, nel modulo stesso, bilanci dettagliati; il file XBRL interattivo della pagina di copertina 猫 indicato come Exhibit 104 e il rapporto 猫 firmato dal Chief Financial Officer della societ脿, Bradley Saenger.
Tonix Pharmaceuticals Holding Corp. inform贸 que public贸 los resultados operativos correspondientes al trimestre cerrado el 30 de junio de 2025. La compa帽铆a se帽ala que el comunicado de prensa que detalla dichos resultados se presenta como Exhibit 99.01 y se incorpora por referencia en este informe. La presentaci贸n confirma que las acciones ordinarias de Tonix cotizan con el s铆mbolo TNXP en The NASDAQ Capital Market.
La presentaci贸n es un aviso de la publicaci贸n de los resultados operativos y no incluye estados financieros detallados dentro del propio formulario; el archivo XBRL interactivo de la portada se menciona como Exhibit 104 y el informe est谩 firmado por el director financiero de la empresa, Bradley Saenger.
Tonix Pharmaceuticals Holding Corp.電� 2025雲� 6鞗� 30鞚�搿� 膦呺霅� 攵勱赴 鞁れ爜鞚� 瓿淀憸頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 須岇偓電� 頃措嫻 鞁れ爜鞚� 靹る獏頃橂姅 氤措弰鞛愲臧� Exhibit 99.01搿� 鞝滌稖霅橃柎 氤� 氤搓碃靹滌棎 彀戈碃 氍疙棇鞙茧 韽暔霅橃柎 鞛堧嫟瓿� 氚濏様鞀惦媹雼�. 鞚� 鞝滌稖靹滊電� Tonix鞚� 氤错喌欤缄皜 TNXP霛茧姅 鞁臣搿� The NASDAQ Capital Market鞐� 靸侅灔霅橃柎 瓯半灅霅橁碃 鞛堨潓鞚� 頇曥澑頃╇媹雼�.
頃措嫻 鞝滌稖靹滊姅 鞏戩嫕 鞛愳泊鞐� 靸侅劯 鞛鞝滍憸毳� 韽暔頃� 瓴冹澊 鞎勲媹霛� 攵勱赴 鞁れ爜 瓿奠嫓 韱奠鞚措┌, 響滌鞚� 雽�頇旐槙 XBRL 韺岇澕鞚� Exhibit 104搿� 彀胳“霅橃柎 鞛堦碃 氤搓碃靹滊姅 須岇偓 鞛毂呾瀯鞛�(CFO) Bradley Saenger鞚� 靹滊獏鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Tonix Pharmaceuticals Holding Corp. a annonc茅 avoir communiqu茅 ses r茅sultats op茅rationnels pour le trimestre clos le 30 juin 2025. La soci茅t茅 indique que le communiqu茅 de presse d茅taillant ces r茅sultats est d茅pos茅 en tant que Exhibit 99.01 et est incorpor茅 par r茅f茅rence dans ce rapport. Le d茅p么t confirme que les actions ordinaires de Tonix sont n茅goci茅es sous le symbole TNXP sur The NASDAQ Capital Market.
Le d茅p么t constitue un avis de publication des r茅sultats op茅rationnels et non des 茅tats financiers d茅taill茅s dans le formulaire lui鈥憁锚me ; le fichier XBRL interactif de la page de garde est r茅f茅renc茅 en tant que Exhibit 104, et le rapport est sign茅 par le directeur financier de la soci茅t茅, Bradley Saenger.
Tonix Pharmaceuticals Holding Corp. teilte mit, dass es die operativen Ergebnisse f眉r das am 30. Juni 2025 beendete Quartal ver枚ffentlicht hat. Das Unternehmen gibt an, dass die Pressemitteilung mit Erl盲uterungen zu diesen Ergebnissen als Exhibit 99.01 eingereicht und durch Verweis in diesen Bericht aufgenommen wurde. Die Einreichung best盲tigt, dass Tonix' Stammaktien unter dem K眉rzel TNXP am The NASDAQ Capital Market gehandelt werden.
Es handelt sich bei der Einreichung um einen Hinweis auf die Ver枚ffentlichung der operativen Ergebnisse und nicht um ausf眉hrliche Finanzabschl眉sse innerhalb des Formulars; die interaktive XBRL-Datei der Titelseite wird als Exhibit 104 angegeben, und der Bericht ist vom Chief Financial Officer des Unternehmens, Bradley Saenger, unterzeichnet.
- None.
- None.
Insights
TL;DR: Routine earnings disclosure filed; no financial detail in the form itself, press release attached as exhibit.
The 8-K notifies investors that the company released its operating results for the quarter ended June 30, 2025, and includes the press release as Exhibit 99.01. Because the form does not contain numerical results or detailed financial statements, the filing primarily serves as a distribution and disclosure mechanism. Investors must review the attached press release and any accompanying XBRL data for substantive metrics such as revenue, net income, or cash flow.
TL;DR: Disclosure follows standard reporting practices; signature by CFO confirms formal filing authority.
The document follows standard Section 2.02 and 9.01 disclosure conventions by notifying the market of released results and formally attaching the press release as an exhibit. The inclusion of the interactive XBRL cover page indicates preparer intent for machine-readable disclosure. The signature by the Chief Financial Officer confirms internal authorization, but the filing itself contains no material operational or governance changes.
Tonix Pharmaceuticals Holding Corp. ha reso noto di aver comunicato i risultati operativi relativi al trimestre chiuso il 30 giugno 2025. La societ脿 indica che il comunicato stampa che illustra tali risultati 猫 depositato come Exhibit 99.01 e viene incorporato per riferimento nel presente rapporto. Il documento conferma che le azioni ordinarie di Tonix sono negoziate con il simbolo TNXP sul NASDAQ Capital Market.
Si precisa che la presente comunicazione riguarda la pubblicazione dei risultati operativi e non contiene, nel modulo stesso, bilanci dettagliati; il file XBRL interattivo della pagina di copertina 猫 indicato come Exhibit 104 e il rapporto 猫 firmato dal Chief Financial Officer della societ脿, Bradley Saenger.
Tonix Pharmaceuticals Holding Corp. inform贸 que public贸 los resultados operativos correspondientes al trimestre cerrado el 30 de junio de 2025. La compa帽铆a se帽ala que el comunicado de prensa que detalla dichos resultados se presenta como Exhibit 99.01 y se incorpora por referencia en este informe. La presentaci贸n confirma que las acciones ordinarias de Tonix cotizan con el s铆mbolo TNXP en The NASDAQ Capital Market.
La presentaci贸n es un aviso de la publicaci贸n de los resultados operativos y no incluye estados financieros detallados dentro del propio formulario; el archivo XBRL interactivo de la portada se menciona como Exhibit 104 y el informe est谩 firmado por el director financiero de la empresa, Bradley Saenger.
Tonix Pharmaceuticals Holding Corp.電� 2025雲� 6鞗� 30鞚�搿� 膦呺霅� 攵勱赴 鞁れ爜鞚� 瓿淀憸頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 須岇偓電� 頃措嫻 鞁れ爜鞚� 靹る獏頃橂姅 氤措弰鞛愲臧� Exhibit 99.01搿� 鞝滌稖霅橃柎 氤� 氤搓碃靹滌棎 彀戈碃 氍疙棇鞙茧 韽暔霅橃柎 鞛堧嫟瓿� 氚濏様鞀惦媹雼�. 鞚� 鞝滌稖靹滊電� Tonix鞚� 氤错喌欤缄皜 TNXP霛茧姅 鞁臣搿� The NASDAQ Capital Market鞐� 靸侅灔霅橃柎 瓯半灅霅橁碃 鞛堨潓鞚� 頇曥澑頃╇媹雼�.
頃措嫻 鞝滌稖靹滊姅 鞏戩嫕 鞛愳泊鞐� 靸侅劯 鞛鞝滍憸毳� 韽暔頃� 瓴冹澊 鞎勲媹霛� 攵勱赴 鞁れ爜 瓿奠嫓 韱奠鞚措┌, 響滌鞚� 雽�頇旐槙 XBRL 韺岇澕鞚� Exhibit 104搿� 彀胳“霅橃柎 鞛堦碃 氤搓碃靹滊姅 須岇偓 鞛毂呾瀯鞛�(CFO) Bradley Saenger鞚� 靹滊獏鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Tonix Pharmaceuticals Holding Corp. a annonc茅 avoir communiqu茅 ses r茅sultats op茅rationnels pour le trimestre clos le 30 juin 2025. La soci茅t茅 indique que le communiqu茅 de presse d茅taillant ces r茅sultats est d茅pos茅 en tant que Exhibit 99.01 et est incorpor茅 par r茅f茅rence dans ce rapport. Le d茅p么t confirme que les actions ordinaires de Tonix sont n茅goci茅es sous le symbole TNXP sur The NASDAQ Capital Market.
Le d茅p么t constitue un avis de publication des r茅sultats op茅rationnels et non des 茅tats financiers d茅taill茅s dans le formulaire lui鈥憁锚me ; le fichier XBRL interactif de la page de garde est r茅f茅renc茅 en tant que Exhibit 104, et le rapport est sign茅 par le directeur financier de la soci茅t茅, Bradley Saenger.
Tonix Pharmaceuticals Holding Corp. teilte mit, dass es die operativen Ergebnisse f眉r das am 30. Juni 2025 beendete Quartal ver枚ffentlicht hat. Das Unternehmen gibt an, dass die Pressemitteilung mit Erl盲uterungen zu diesen Ergebnissen als Exhibit 99.01 eingereicht und durch Verweis in diesen Bericht aufgenommen wurde. Die Einreichung best盲tigt, dass Tonix' Stammaktien unter dem K眉rzel TNXP am The NASDAQ Capital Market gehandelt werden.
Es handelt sich bei der Einreichung um einen Hinweis auf die Ver枚ffentlichung der operativen Ergebnisse und nicht um ausf眉hrliche Finanzabschl眉sse innerhalb des Formulars; die interaktive XBRL-Datei der Titelseite wird als Exhibit 104 angegeben, und der Bericht ist vom Chief Financial Officer des Unternehmens, Bradley Saenger, unterzeichnet.
FAQ
What did Tonix Pharmaceuticals (TNXP) report in this 8-K?
Where is Tonix Pharmaceuticals (TNXP) listed?
Does this 8-K include detailed financial statements or results?
Who signed the 8-K for Tonix Pharmaceuticals?
How can I find the operating results mentioned in the filing?
